Historical antecedents of inflammatory bowel disease therapy
โ Scribed by Dr. Joseph B. Kirsner
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 985 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
โฆ Synopsis
The increasingly "scientific" approach to the treatment of inflammatory bowel disease (IBD), that is, therapeutic interventions based on research, for example, in the development of anti-inflammatory agents to suppress pro-inflammatory molecules, is in sharp contrast to the arbitrary and sometimes bizarre approaches often utilized in the past. The purpose of this article is to provide a historical account of such earlier therapeutic approaches to emphasize the progress achieved in the treatment of IBD.
OLD AND NEW MEDICAL THERAPY
Past therapeutic approaches to ulcerative colitis and Crohn's disease reflected prevailing notions and misconceptions of human illness. The treatment of IBD during the early 1900s included "slop diets," three pints daily of milk soured by lactic acid, "vaccines," astringents, antiseptics, opium, tincture of hamamaelis, tincture of iodine, and rectal instillations of boracic acid, silver nitrate, creolin, iron pernitrate, or kerosene (1)-strange therapy to physicians of the 1990s, but hardly as bizarre as the approach of ancient times to diarrhea and associated problems as described in the following:
Once upon a time, a King, following a large repast, experienced a sudden abdominal cramping pain followed by severe watery diarrhea and then lapsed into a coma. The following treatment was employed by the royal physicians: A pint of blood was extracted from his right arm; then eight ounces from the left shoulder; next an emetic, two physics, and an enema consisting of 15 substances were admin-
๐ SIMILAR VOLUMES
Despite recent advances, the therapeutic armamentarium for inflammatory bowel disease (IBD) is still limited. In addition, a step-up approach is recommended for most IBD patients. Thus, optimizing each medical therapy before switching to another drug class is the rule in clinical practice. Conventio
Background: Mycophenolate mofetil (MMF) is an immunomodulatory drug, and its use in inflammatory bowel disease has previously been reported. The aim of this study was to review the Leeds Colitis Clinic experience of the safety and efficacy of MMF in treating patients with refractory Crohn's disease
About 30% of individuals with inflammatory bowel disease present before the age of 21 years (1). Despite this prevalence, most therapeutic agents are tested in adults with inflammatory bowel disease and pharmacokinetics, safety, and efficacy may never be studied in children and adolescents. In this